Spectrophotometric Determination of Ru(III) with Trifluoperazine Dihydrochloride

631-63

Direct exchange endoprosthetic reconstruction with tumour prosthesis for periprosthetic knee infection associated with segmental bone defects

Revision knee arthroplasty for infection poses a treatment challenge. The presence of massive osteolysis limits the treatment options in this cohort. Controversy exists in the management of these patients. Direct exchange arthroplasty has provided good results in the presence of infection, but whether this is appropriate in the presence of massive bone defects associated with the infection is undetermined. We present our experience in revision knee arthroplasty for infection associated with massive bone defects. The aim of the study is to present the preliminary results of a direct exchange endoprosthetic reconstruction with tumour prosthesis for periprosthetic infection associated with segmental bone defects. This is a retrospective study of prospectively collected data, involving six patients with periprosthetic infection and massive bone defects treated by direct exchange tumour prostheses between 2003 and 2007 (four distal femoral replacements and two total femoral replacements). The mean age and follow-up were 74.2 (±5.2) years and 32.5 (±8.2) months respectively. Each patient had an infected revised knee arthroplasty at the time of referral to our institution. Staphylococcus aureus was the most common causal organism. The mean duration of antibiotics was 6 weeks intravenous therapy followed by 3.5 months oral. The recurrences of infection, pain or immobility were outcome criteria considered failures. Our success rate was 80%. Salvage of infected revised knee arthroplasty by direct exchange endoprosthetic reconstruction has provided an effective means of pain relief, joint stability and improved mobility in our cohort. It reduces morbidity through earlier mobilisation and avoids a second major operation

Evaluation of efficacy and safety of bilastine 20 mg tablets in adult patients with allergic rhinitis

Background: Bilastine is a nonsedating, H1-antihistamine used for symptomatic treatment of allergic rhinitis; However, data on its efficacy and safety in Indian patients with allergic rhinitis are lacking.Methods: In this multicenter, single-arm, investigator-initiated study, 90 patients with allergic rhinitis received bilastine 20 mg tablets once daily for 4 weeks. The primary endpoint was change in total symptom score (TSS=nasal symptom score [NSS] + non-nasal symptom score [NNSS]) at day 28 from baseline. Severity of individual nasal and non-nasal symptoms was assessed at baseline, day 7, and day 28 by rating each symptom on a scale of 0-3. Key secondary endpoints were incidence of treatment-emergent adverse events (TEAEs), changes in NSS, NNSS, and rhinoconjunctivitis quality of life questionnaire (RQLQ) score, and from baseline to days 7 and 28, and change in Stanford sleepiness scale (SSS) score from baseline to 2 hours post-first dose.Results: The mean allergic rhinitis symptom scores TSS, NSS and NNSS showed a significant decrease (p˂0.0001) at each visit compared with baseline. A statistically significant decline (p˂0.0001) in the mean RQLQ score was observed at days 7 and 28 versus baseline. Median SSS score was 1.0 (range: 1.0-7.0) before and after the 1st dose of bilastine, indicating that it did not cause sedation. No TEAEs were reported during the study.Conclusions: Bilastine 20 mg once daily was efficacious in reducing nasal and non-nasal allergic symptoms, was well tolerated, and had a good safety profile in patients with allergic rhinitis

Role of oral misoprostol 600 mcg in active management of third stage of labour: a comparative study with carboprost 125 mcg, intramuscular

Background: Objectives: To compare misoprostol 600 mcg, oral with carboprost 125 mcg, i.m., in the active management of third stage of labour.Methods: A total of 200 pregnant women of 38-42 weeks of gestation delivering vaginally in the Shivamogga institute of medical sciences, Shivamogga, Karnataka, India were selected for study. 100 women received misoprostol 600 mcg, orally and 100 women received carboprost 125 mcg, i.m. immediately after delivery of baby and cord clamping by the method of randomisation.Results: In the misoprostol group, mean blood loss is 134.9 ml, mean duration of the third stage of labour is 4.07 min and mean fall in hemoglobin is 0.34 g/dl. In the carboprost group, mean blood loss is 123.7 ml, mean duration of the third stage of labour is 3.73 min and mean fall in hemoglobin is 0.28 g/dl. There was no significant difference between the two groups with regard to the above mentioned factors. There were 5 cases of PPH in the misoprostol group and 3 cases in the carboprost group. 21 cases in the misoprostol group and 14 cases in the carboprost group required additional oxytocics. Unpleasant side effects like diarrhoea and vomiting were more in carboprost group.  Conclusion: Oral misoprostol is as effective as carboprost in AMTSL and can be used safely in vaginal deliveries for prevention of PPH, especially in non-institutional deliveries and in places of low resource settings.

TGA studies of metoclopramide complexes of cobalt(II) in the solid state

A new series of cobalt(II) complexes with metoclopramide (MCP) ligand have been prepared. The prepared Co(II)-MCP complexes were characterized for various analytical techniques. Conductivity and elemental analysis of complexes have been measured. The thermal stability and degradation kinetics have been measured using thermogravimetric analyser. Kinetic parameter was obtained for each stage of thermal degradation for Co(II)-MCP complexes using Horowitz-Metzger, Coats-Redfern and Broido's methods. The activation energy (Ea) of the complexes for the thermal degradation process lie in the range 31-168, 23-161 and 33-170 kJ mol-1 for Horowitz-Metzger, Coats-Redfern and Broido's methods, respectively. © 2003 Elsevier B.V. All rights reserved

Synthesis, characterization and antimicrobial activity evaluation of new imidazo [2,1-b][1,3,4]thiadiazole derivatives

Imidazo[2,1-b][1,3,4]thiadiazoles (4a-g) were synthesized from 3,4,5-trimethoxy benzoic acid and thiosemicarbazide. Reaction of 4 with Vilsmeier-Haack reagent yielded imidazo [2,1-b][1,3,4] thiadiazole–5-carbaldehyde derivatives (5a-g). Obtained imidazo[2,1-b][1,3,4] thiadia zoles-5-carbaldehydes were subjected to Knoevenagel condensation with 2-(2,4-dioxothia zolidin-3-yl)acetic acid (1) and 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic (2) in the presence of catalytic amount of piperidine and acetic acid to afford imidazo[2,1-b][1,3,4]thiadiazoles (6a-g) and (7a-g), respectively. The structures of the newly synthesized compounds were confirmed by IR, NMR and elemental analyses. All compounds were screened for their antibacterial and antifungal activities. Some of the compounds displayed good antibacterial and antifungal activity

Spectrophotometric Determination of Pd(U) using Prochlorperazine Maleate as Reagent

454-45